Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 725 of 866 entries
View as:

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

Phase: N/A Priority: Normal
NCT ID: NCT05686980 Org: User:
Start: 01/17/23 End: 03/30/23 Due: 03/30/24

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

Phase: N/A Priority: Normal
NCT ID: NCT03712787 Org: User:
Start: 03/22/19 End: 09/30/21 Due: 09/30/22

To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01199224 Org: User:
Start: 06/30/10 End: 11/30/10 Due: 11/30/11

A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06571266 Org: User:
Start: 09/11/24 End: 04/16/25 Due: 04/16/26

A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration

Phase: N/A Priority: Normal
NCT ID: NCT06278766 Org: User:
Start: 02/21/24 End: 04/19/24 Due: 04/19/25

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Phase: N/A Priority: Normal
NCT ID: NCT06093503 Org: User:
Start: 05/31/24 End: 04/11/28 Due: 04/11/29

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT05814627 Org: User:
Start: 06/15/23 End: 08/31/26 Due: 08/31/27

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Phase: N/A Priority: Normal
NCT ID: NCT03738215 Org: User:
Start: 11/09/18 End: 09/30/21 Due: 09/30/22

An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Phase: N/A Priority: Normal
NCT ID: NCT05411211 Org: User:
Start: 11/10/22 End: 09/08/24 Due: 09/08/25

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT03398135 Org: User:
Start: 08/28/18 End: 09/30/28 Due: 09/30/29

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03000075 Org: User:
Start: 12/02/16 End: 06/20/18 Due: 06/20/19

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT02590263 Org: User:
Start: 08/24/15 End: 08/27/20 Due: 08/27/21

Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada

Phase: N/A Priority: Normal
NCT ID: NCT06692881 Org: User:
Start: 02/12/25 End: 01/31/26 Due: 01/31/27

Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting

Phase: N/A Priority: Normal
NCT ID: NCT02786576 Org: User:
Start: 07/05/16 End: 01/07/19 Due: 01/07/20

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02674568 Org: User:
Start: 01/25/16 End: 10/19/18 Due: 10/19/19

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03222609 Org: User:
Start: 10/31/17 End: 01/29/25 Due: 01/29/26

A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154

Phase: N/A Priority: Normal
NCT ID: NCT04972968 Org: User:
Start: 09/09/21 End: 07/24/23 Due: 07/24/24

Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder

Phase: N/A Priority: Normal
NCT ID: NCT06256367 Org: User:
Start: 04/18/24 End: 07/31/25 Due: 07/31/26

Expanded Access to Upadacitinib

Phase: N/A Priority: Normal
NCT ID: NCT04159597 Org: User:
Start: - End: - Due: -

Expanded Access to Elezanumab

Phase: N/A Priority: Normal
NCT ID: NCT04278235 Org: User:
Start: - End: - Due: -

A Study of ABT-165 in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01946074 Org: User:
Start: 08/08/13 End: 09/28/22 Due: 09/28/23

A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT00526617 Org: User:
Start: 08/31/07 End: - Due: -

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT02065557 Org: User:
Start: 10/13/14 End: 02/07/20 Due: 02/07/21

Expanded Access to Navitoclax

Phase: N/A Priority: Normal
NCT ID: NCT03592576 Org: User:
Start: - End: - Due: -

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06318273 Org: User:
Start: 03/08/24 End: 05/31/27 Due: 05/31/28